GlassScriptPhysician profile
Shawn Kernz
NPI 1942987078
$1,576.07
in general payments reported to CMS, 2019-2025
12 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $632 · 2024: $819 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,576.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,576.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $286.78 | 2023-2024 | Azstarys |
| Abbvie INC. | $286.01 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $241.50 | 2023-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $139.77 | 2023-2024 | Spravato, Invega Sustenna |
| Alkermes, INC. | $139.65 | 2023-2024 | Aristada, Lybalvi, Aristada Initio |
| Axsome Therapeutics, INC. | $125.00 | 2025 | Auvelity |
| Noven Therapeutics, LLC | $92.72 | 2023-2024 | Xelstrym, Secuado |
| Indivior INC. | $84.97 | 2024 | Sublocade, Perseris |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $80.93 | 2024 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $40.75 | 2024 | Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $36.80 | 2024 | Trintellix |
| Supernus Pharmaceuticals, INC. | $21.19 | 2024 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shawn Kernz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.